Cantabio Pharmaceuticals and Purdue Research Foundation Sign Cooperation Agreement to Investigate the Targeting of DJ-1 Protein for Treating Parkinson’s Disease and Other Neurodegenerative Diseases

SAN FRANCISCO and WEST LAFAYETTE, Ind., July 11, 2016 (GLOBE NEWSWIRE) — Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced the signing of an agreement with Purdue Research Foundation (PRF) to advance the company’s development work on targeting DJ-1...